On Friday, Relay Therapeutics Inc (NASDAQ: RLAY) opened at On Friday, higher 3.70% from the last session, before settling in for the closing price of $3.24. Price fluctuations for RLAY have ranged from $1.77 to $10.72 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 21.05% at the time writing. With a float of $129.27 million, this company’s outstanding shares have now reached $170.48 million.
Let’s look at the performance matrix of the company that is accounted for 261 employees. In terms of profitability, gross margin is -12.15%, operating margin of -4927.05%, and the pretax margin is -4341.53%.
Relay Therapeutics Inc (RLAY) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Relay Therapeutics Inc is 24.60%, while institutional ownership is 83.57%. The most recent insider transaction that took place on Apr 30 ’25, was worth 32,217. In this transaction an insider of this company sold 10,739 shares at a rate of $3.00, taking the stock ownership to the 390,081 shares. Before that another transaction happened on Apr 28 ’25, when Company’s insider sold 1,364 for $3.17, making the entire transaction worth $4,324. This insider now owns 400,820 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.45 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.83% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Check out the current performance indicators for Relay Therapeutics Inc (RLAY). In the past quarter, the stock posted a quick ratio of 19.96. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 75.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.23, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc (NASDAQ: RLAY) saw its 5-day average volume 1.45 million, a negative change from its year-to-date volume of 2.36 million. As of the previous 9 days, the stock’s Stochastic %D was 79.28%. Additionally, its Average True Range was 0.23.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 48.48%, which indicates a significant decrease from 87.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.31% in the past 14 days, which was lower than the 84.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.86, while its 200-day Moving Average is $4.66. Nevertheless, the first resistance level for the watch stands at $3.44 in the near term. At $3.53, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.61. If the price goes on to break the first support level at $3.28, it is likely to go to the next support level at $3.20. Assuming the price breaks the second support level, the third support level stands at $3.11.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
There are currently 171,445K shares outstanding in the company with a market cap of 576.06 million. Presently, the company’s annual sales total 10,010 K according to its annual income of -337,710 K. Last quarter, the company’s sales amounted to 7,680 K and its income totaled -77,070 K.
